An anterior chamber toxicity study evaluating besivance, azasite, and ciprofloxacin

American Journal of Ophthalmology

Volumn 150, Issue 4, 2010, Pages

  Ness, Peter J ^a   Mamalis, Nick ^a   Werner, Liliana ^a   Maddula, Surekha ^a   Davis, Don K ^a   Donnenfeld, Eric D ^b   Olson, Randall J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZASITE; AZITHROMYCIN; BESIVANCE; CIPROFLOXACIN; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; 7-(3-AMINOHEXAHYDRO-1H-AZEPIN-1-YL)-8-CHLORO-1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLINECARBOXYLIC ACID; ACETIC ACID DERIVATIVE; ANTIINFECTIVE AGENT; AZEPINE DERIVATIVE; BALANCED SALT SOLUTION; DRUG COMBINATION; MINERAL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANTERIOR EYE CHAMBER; ARTICLE; CELL DENSITY; CONTROLLED STUDY; CORNEA EDEMA; DRUG EFFECT; ENDOTHELIUM CELL; EYE CHAMBER DISEASE; EYE TOXICITY; KERATOPATHY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RABBIT; VITAL STAIN; ANIMAL; CHEMICALLY INDUCED; COMPARATIVE STUDY; CORNEA OPACITY; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; RANDOMIZATION; TRABECULAR MESHWORK;

ACETATES; ANIMALS; ANTERIOR CHAMBER; ANTI-BACTERIAL AGENTS; AZEPINES; AZITHROMYCIN; CIPROFLOXACIN; CORNEAL OPACITY; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; FEMALE; FLUOROQUINOLONES; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; MINERALS; RABBITS; RANDOM ALLOCATION; SODIUM CHLORIDE; TRABECULAR MESHWORK;

EID: 77957284769     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.05.006     Document Type: Article

References (18)

1. A. Behrens, W.J. Stark, K.A. Pratzer, and P.J. McDonnell Dynamics of small-incision clear cornea wounds after phacoemulsification surgery using optical coherence tomography in the early postoperative period J Refract Surg 24 1 2008 46 49
2. S. Herretes, W.J. Stark, A. Pirouzmanesh, J.M. Reyes, P.J. McDonnell, and A. Behrens Inflow of ocular surface fluid into the anterior chamber after phacoemulsification through sutureless corneal cataract wounds Am J Ophthalmol 140 4 2005 737 740 (Pubitemid 41455325)
3. M. Taban, M.A. Sarayba, T.S. Ignacio, A. Behrens, and P.J. McDonnell Ingress of India ink into the anterior chamber through sutureless clear corneal cataract wounds Arch Ophthalmol 123 5 2005 643 648 (Pubitemid 40695512)
4. L. Werner, O. Yeh, J. Haymore, B. Haugen, N. Romaniv, and N. Mamalis Corneal endothelial safety with the irradiation system for light-adjustable intraocular lenses J Cataract Refract Surg 33 5 2007 873 878 (Pubitemid 46656447)
5. D.J. Spence, and G.A. Peyman A new technique for the vital staining of the corneal endothelium Invest Ophthalmol 15 12 1976 1000 1002
6. M.R. Tetz, G.U. Auffarth, M. Sperker, M. Blum, and H.E. Volcker Photographic image analysis system of posterior capsule opacification J Cataract Refract Surg 23 10 1997 1515 1520 (Pubitemid 28047511)
7. K.K. Williams, R.L. Noe, H.E. Grossniklaus, C. Drews-Botsch, and H.F. Edelhauser Correlation of histologic corneal endothelial cell counts with specular microscopic cell density Arch Ophthalmol 110 8 1992 1146 1149
8. T.P. O'Brien, S.A. Arshinoff, and F.S. Mah Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin J Cataract Refract Surg 33 10 2007 1790 1800 (Pubitemid 47432836)
9. M.E. Tepedino, W.H. Heller, and D.W. Usner Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis Curr Med Res Opin 25 5 2009 1159 1169
10. M.E. Sanders, E.W. Norcross, Q.C. Moore 3rd, A. Shafiee, and M.E. Marquart Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis Cornea 28 9 2009 1055 1060
11. M.B. McDonald, E.E. Protzko, and L.S. Brunner Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis Ophthalmology 116 9 2009 1615 1623
12. W. Haas, C.M. Pillar, G.E. Zurenko, J.C. Lee, L.S. Brunner, and T.W. Morris Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria Antimicrob Agents Chemother 53 8 2009 3552 3560
13. J.Z. Zhang, and K.W. Ward Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes J Antimicrob Chemother 61 1 2008 111 116
14. E. Protzko, L. Bowman, M. Abelson, and A. Shapiro Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis Invest Ophthalmol Vis Sci 48 8 2007 3425 3429 (Pubitemid 351261073)
15. M.S. Dorfman, R.S. Wagner, T. Jamison, B. Bell, and D.W. Stroman The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment Adv Ther 25 3 2008 208 217
16. S.H. Park, J.A. Lim, J.S. Choi, K.A. Kim, and C.K. Joo The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics Cornea 28 1 2009 68 72
17. L. Werner, J.H. Sher, and J.R. Taylor Toxic anterior segment syndrome and possible association with ointment in the anterior chamber following cataract surgery J Cataract Refract Surg 32 2 2006 227 235 (Pubitemid 44809596)
18. K. Green, D. Hull, E. Vaughn, A. Malizia, and K. Bowman Rabbit endothelial response to toxic preservatives Arch Ophthalmol 95 12 1977 2218 2221 (Pubitemid 8261065)